![]() The clinical characteristics of the twenty patients (ten malignant patients and ten benign patients) was summarized in Table 1. The clinical information included in the study were age, gender, pathology subgroup, location, progression-specific survival (PFS), and overall survival (OS). Twenty meningioma patients were enrolled, and the patients had surgery between 20 at Beijing Tiantan Hospital. In the study, we focus on the prognostic factors and the potential compounds in the malignant progression of meningioma. Subsequently, further study on the underlying and important driven genes of meningioma and the potential compounds is desired. ![]() Regardless of extraordinary efforts invested in the study of meningioma, the prognosis and treatment stayed unfavorable. And, several studies have shown that trabectedin, multi-kinase inhibitors, and bevacizumab could be used as the adjuvant treatment, but the results were unsatisfactory 8, 9, 10. Presently, the main treatment of meningioma was the surgery, and the adjuvant treatment (radiosurgery or fractionated external beam RT). In addition, the meningioma with filtration of surrounding brain parenchyma was associated with poor outcome and recurrence 4, 5, 6, 7. It has fifteen kinds of subgroups, and the malignant meningioma includes atypical meningioma and the WHO 3 meningioma 2, 3. Meningioma accounts for 36.3% of primary intracranial neoplasms, and the occurrence rate was about 6–7 per 100,000 individuals 1.
0 Comments
Leave a Reply. |